The association between neuroleptic treatment and the negative symptom dimension (ND) was evaluated in 1528 schizophrenia patients. In patients receiving more than 820 mg chlorpromazine (CPZ), those with catatonic-type disorder had significantly (p<0.05) higher ND scores than those in any of the other diagnostic subtypes. Even in patients receiving 450 mg CPZ or more, catatonic patients had significantly (p=0.046) higher ND scores than other patients. Patients with catatonic schizophrenia are highly vulnerable to negative symptoms related to neuroleptic drugs, probably because of a defect in their dopaminergic neuronal pathways.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0920-9964(02)00155-x | DOI Listing |
Publication Analysis
Top Keywords
negative symptoms
4
symptoms neuroleptics
4
neuroleptics catatonic
4
catatonic schizophrenia
4
schizophrenia association
4
association neuroleptic
4
neuroleptic treatment
4
treatment negative
4
negative symptom
4
symptom dimension
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!